Compare CYD & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CYD | CERT |
|---|---|---|
| Founded | 1951 | 2008 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Retail: Computer Software & Peripheral Equipment |
| Sector | Industrials | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 1998 | 2020 |
| Metric | CYD | CERT |
|---|---|---|
| Price | $23.32 | $11.70 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 13 |
| Target Price | ★ $56.70 | $9.17 |
| AVG Volume (30 Days) | 212.7K | ★ 2.6M |
| Earning Date | 08-07-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.72% | N/A |
| EPS Growth | N/A | ★ 87.50 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $418,838,000.00 |
| Revenue This Year | $13.33 | N/A |
| Revenue Next Year | $8.69 | $2.57 |
| P/E Ratio | $32.71 | ★ N/A |
| Revenue Growth | N/A | ★ 8.75 |
| 52 Week Low | $23.08 | $4.45 |
| 52 Week High | $61.48 | $11.88 |
| Indicator | CYD | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 25.35 | 75.19 |
| Support Level | N/A | $6.15 |
| Resistance Level | $35.66 | N/A |
| Average True Range (ATR) | 1.17 | 0.53 |
| MACD | -0.05 | 0.16 |
| Stochastic Oscillator | 8.57 | 98.66 |
China Yuchai International Ltd is a Bermuda holding company that is a subsidiary of Singapore-based Hong Leong Asia. China Yuchai International operates through its majority-owned subsidiary Guangxi Yuchai Machinery Company, a China-based company that manufactures, assembles, and distributes diesel engines for various vehicles including trucks, buses, and cars, as well as construction and agricultural, marine, and power-generation equipment. It generates the majority of its sales from the Chinese market.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.